Bausch Health Companies Inc. (NYSE:BHC) finished Thursday with an addition of $0.05 to close at $7.15, an upside of 0.70 percent. An average of 7,054,660 shares of common stock have been traded in the last five days. There was a fall of -$0.49 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 11,021,445 shares traded, while the 50-day average volume stands at 9,921,200.
BHC stock has increased by 35.93% in the last month. The company shares reached their 1-month lowest point of $4.99 on 08/30/22. With the stock rallying to its 52-week high on 01/05/22, shares of the company touched a low of $4.00 and a high of $29.58 in 52 weeks. It has reached a new high 3 times so far this year and lost -74.10% or -$20.46 in price. In spite of this, the price is down -75.83% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
114 days have passed since Bausch Health Companies Inc. (BHC) last reported insider trading activity. Bausch Health Companies Inc., who is 10% Owner, most recently acquired $4,550,357 shares at $17.05 per share on Jun 01. In this transaction, the insider spent $77,606,339. 10% Owner, Bausch Health Companies Inc., disposed of 35,000,000 shares at a price of $17.05 on May 10. The insider now owns more than $596,925,000 worth of shares. Prior to that, U.S. President-Pharma Business Spurr Robert went on to Sale 1,595 shares at $22.19 each on Apr 14. An amount of $35,393 was transacted.
Bausch Health Companies Inc. (BHC) has a trailing price-to-earnings (P/E) ratio of 61.11. The stock’s beta is 1.16. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.33, and the price-to-cash flow ratio at 6.55.
The quick ratio of Bausch Health Companies Inc. for the three months ended June 29 was 0.90, and the current ratio was 1.10, indicating that the company is not able to meet its debt obligations. Its gross profit as reported stood at $6.04 billion compared to revenue of $8.43 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Bausch Health Companies Inc.’s return on assets was 0.10%.
For the three-month period that ended June 29, Bausch Health Companies Inc. had $21.66 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$145.0 million in the quarter, while revenues were shrunk -310.34%. The analyst consensus anticipated Bausch Health Companies Inc.’s latest quarter earnings to come in at $1.19 per share, but it turned out to be $0.75, a -37.00% surprise. For the quarter, EBITDA amounted to $558.0 million. Shareholders own equity worth $361.73 million.
From a technical analysis perspective, let’s take a brief look at Bausch Health Companies Inc. (BHC) price momentum. RSI 9-day as of the close on 22 September was 55.58%, suggesting the stock is Neutral, with historical volatility in this time frame at 69.37%.
As of today, BHC’s price is $7.23 -6.41% or -$0.49 from its 5-day moving average. BHC is currently trading +35.67% higher than its 20-day SMA and -62.39% lower than its 100-day SMA. However, the stock’s current price level is -20.56% below the SMA50 and -70.62% below the SMA200.
The stochastic %K and %D were 56.90% and 63.38%, respectively, and the average true range (ATR) was 0.55. With the 14-day stochastic at 53.97% and the average true range at 0.57, the RSI (14) stands at 55.08%. The stock has reached -0.23 on the 9-day MACD Oscillator while the 14-day reading was at -0.03.
Truist downgraded Bausch Health Companies Inc. (NYSE: BHC) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for Bausch Health Companies Inc. (BHC) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell BHC, while 6 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is BHC’s price target for the next 12 months?
Analysts predict a range of price targets between $5.00 and $40.00, with a median target of $8.00. Taking a look at these predictions, the average price target given by analysts for Bausch Health Companies Inc. (BHC) stock is $13.67.